(Q40957442)

English

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

scientific article published on 5 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 September 2017

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study (English)

1 reference

Europe PubMed Central

25 September 2017

0 references

1 reference

ChEBI release 2020-05-28

Hepatitis C virus

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

8

object named as

Stanislas Pol

1 reference

Europe PubMed Central

25 September 2017

author name string

David Roth

1

1 reference

Europe PubMed Central

25 September 2017

David R Nelson

2

1 reference

Europe PubMed Central

25 September 2017

Annette Bruchfeld

3

1 reference

Europe PubMed Central

25 September 2017

AnnMarie Liapakis

4

1 reference

Europe PubMed Central

25 September 2017

Marcelo Silva

5

1 reference

Europe PubMed Central

25 September 2017

Howard Monsour

6

1 reference

Europe PubMed Central

25 September 2017

Paul Martin

7

1 reference

Europe PubMed Central

25 September 2017

Maria-Carlota Londoño

9

1 reference

Europe PubMed Central

25 September 2017

Tarek Hassanein

10

1 reference

Europe PubMed Central

25 September 2017

Philippe J Zamor

11

1 reference

Europe PubMed Central

25 September 2017

Eli Zuckerman

12

1 reference

Europe PubMed Central

25 September 2017

Shuyan Wan

13

1 reference

Europe PubMed Central

25 September 2017

Beth Jackson

14

1 reference

Europe PubMed Central

25 September 2017

Bach-Yen Nguyen

15

1 reference

Europe PubMed Central

25 September 2017

Michael Robertson

16

1 reference

Europe PubMed Central

25 September 2017

Eliav Barr

17

1 reference

Europe PubMed Central

25 September 2017

Janice Wahl

18

1 reference

Europe PubMed Central

25 September 2017

Wayne Greaves

19

1 reference

Europe PubMed Central

25 September 2017

language of work or name

0 references

publication date

5 October 2015

1 reference

Europe PubMed Central

25 September 2017

1 reference

Europe PubMed Central

25 September 2017

386

1 reference

Europe PubMed Central

25 September 2017

10003

1 reference

Europe PubMed Central

25 September 2017

1537-1545

1 reference

Europe PubMed Central

25 September 2017

Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

HCV infection and the incidence of CKD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus infection and de novo glomerular lesions in renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-invasive evaluation of liver fibrosis using transient elastography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900349-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)00349-9

1 reference

Europe PubMed Central

25 September 2017

1 reference

Europe PubMed Central

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40957442&oldid=1911135240"